Multidrug-resistant (MDR) Enterobacteriaceae are often related to the production of extended-spectrum blactamases (ESBLs) and carbapenemase-producing Enterobacteriaceae (CRE), and represent an increasing global threat. Recommendations for the therapeutic management of MDR-related infections, however, are mainly derived from retrospective and nonrandomized prospective studies. The aim of this review is to discuss the challenges in the treatment of patients with infections because of MDR Enterobacteriaceae and provide an expert opinion while awaiting for more definitive data.
INTRODUCTION
Multidrug-resistant (MDR) Enterobacteriaceae infections are often caused by extended-spectrum b-lactamases (ESBLs) and carbapenemase-producing strains and represent an increasing global threat [1] [2] [3] . Over the years, a number of important issues in managing patients with infections caused by these pathogens have emerged. They include the complexity of the underlying mechanism of resistance, the choice and timing of empiric or targeted treatment, the antimicrobial dosing, and the choice of monotherapy vs. combination treatment [4] . The aim of this review is to describe the current controversies concerning the optimal therapeutic approaches to MDR Enterobacteriaceae infections and to provide an expert opinion for treatment options in the absence of more definitive data.
EMPIRICAL TREATMENT
Inadequate empirical antimicrobial therapy of severe infections caused by MDR Enterobacteriaceae has been associated with an increased morbidity and mortality [5,6 && ]. To avoid the overuse of broad-spectrum antibiotics, a careful selection of patients who may receive empirical treatment covering MDR Enterobacteriaceae is important. As
The main dilemma in infections caused by ESBL-producing Enterobacteriaceae is the best use of carbapenems. To avoid the threat of carbapenemase-producing Enterobacteriaceae, carbapenem-saving strategies have been proposed and alternative therapeutic approaches should be considered for the treatment of ESBL infections.
b-lactams
Carbapenems Carbapenems have long been considered the treatment of choice against serious infections caused by ESBL-producing bacteria. Most studies evaluated imipenem or meropenem use, whereas limited experience has been reported with ertapenem, which may represent a valid alternative to avoid the selective pressure for Pseudomonas aeruginosa or Acinetobacter baumannii [14 && ]. As some concerns are rising regarding the isolated resistance to ertapenem, the administration of this drug is recommended at high dosages with extended infusion for patients with isolates showing in-vitro activity [minimum inhibitory concentration (MIC) 0.25 mg/l] and further studies are needed for patients with severe sepsis or septic shock [14 && ,15 & ].
b-lactam/b-lactamase inhibitor combinations b-lactam/b-lactamase inhibitor (BLBLI) combinations, such as piperacillin-tazobactam, have been recommended as an alternative to carbapenems for ESBLs [16 && ,17] . In clinical practice, BLBLIs are often perceived as inferior in the treatment of infections by ESBL producers, although there are no data strongly supporting this evidence [16 && ]. The most relevant studies on this topic are represented by two observational studies on patients with bloodstream infections (BSIs) caused by ESBL, which came to different conclusions. In a recent study by Tamma et al. [18 && ] on BSIs because of various ESBL-producing Enterobacteriaceae (Escherichia coli, Klebsiella spp. or Proteus spp.), patients receiving piperacillin-tazobactam had almost two times higher risk of dying compared with those who were empirically treated with carbapenems. This finding was not confirmed by a recent multinational, retrospective cohort study by Gutiérrez-Gutiérrez et al. [19] that showed that BLBLIs, if active in vitro, appear to be as effective as carbapenems for empirical and targeted BSI because of ESBL Enterobacteriaceae, regardless of the source and specific species if used at appropriate doses. The results of a randomized controlled study (MERINO trial) comparing piperacillin-tazobactam vs. meropenem for the definitive treatment of BSIs caused by ceftriaxone nonsusceptible E. coli and Klebsiella spp. are currently ongoing and its results are urgently awaited [20] .
KEY POINTS
To avoid the threat of CRE, carbapenem-saving strategies should be considered for ESBL infections and infections with MDR organisms with high MIC to carbapenems (MIC to meropenem higher than 8-16 mg/l).
The knowledge of pharmacodynamic and pharmacokinetic properties of antibiotics is paramount to maximize the impact of therapeutic approaches against infections caused by CRE.
The best alternative to carbapenems for the treatment of ESBL infections is represented by BLBLIs, mainly piperacillin-tazobactam MIC 16/4 mg/ml or less.
Overall, combination therapy may be preferred over monotherapy for CRE.
In KPC-Kp with meropenem MIC 8-16 mg/l or less, the combination of a carbapenem-containing regimen (administered with high-dosed, prolonged infusion) with colistin or high-dose tigecycline or aminoglycoside can be administered with TDM.
In KPC-Kp with meropenem MIC higher than 8-16 mg/ l, the use of carbapenem should be avoided and various combination therapies based on the in-vitro susceptibility of antimicrobials (e.g., colistin, high-dose tigecycline, fosfomycin, and aminoglycosides) should be selected.
Strict infection control measures and new therapeutic options toward MDR Gram-negative pathogens are warranted.
Other b-lactams
Among other b-lactams, there is still poor information about the efficacy of active cephalosporins and they are likely to result in treatment failure (even with in-vitro susceptibility). However, cephalosporin-b-lactamase inhibitors, namely ceftolozane-tazobactam and ceftazidime-avibactam, are novel agents that appear to have greater activity against ESBL-producing organisms [21] .
Cephamycins have shown to be stable against hydrolysis by ESBLs. Old cephamycins are avoided for the risk of resistance but a recent multicentric retrospective study [22] has provided insight into the possibility of using a newer cephamycin (e.g., cefmetazole and flomoxef). Another promising treatment option includes temocillin [23] .
Other antibiotics
Tigecycline There are scarce in-vivo data on the efficacy of tigecycline in infections caused by ESBL but overall it seems to be a therapeutic option [24] . Tigecycline used alone or in combination has shown to be effective (63-91%) against nonurinary infections (mainly intra-abdominal infections and skin and soft tissue infection) caused by MDR pathogen, including ESBL Enterobacteriaceae [25, 26] .
Aminoglycosides
The experience of monotherapy with aminoglycosides is limited and is not recommended [15 & ]. The association of b-lactams and aminoglycosides has shown in-vitro synergy [27] and could be used in combination with other drugs in selected patients (mostly in urinary tract and abdominal infections) with confirmed or suspected ESBL to avoid the use of carbapenems ( Fig. 1 ; Table 2 ). 
Fosfomycin
The oral formulation of fosfomycin is used for the treatment of acute uncomplicated urinary tract infection in selected cases [28] . In Europe, the intravenous formulation of fosfomycin is available. According to a recent review, the susceptibility to fosfomycin of ESBL-producing Enterobacteriaceae is high (95.1% for E. coli and 83.8% for K. pneumoniae), although decreasing susceptibility of ESBL-producing E. coli and Klebsiella spp. to fosfomycin have been recently reported [29, 30] . Clinical and pharmacokinetic/pharmacodynamics (PK/PD) data about the efficacy of intravenous fosfomycin against ESBL invasive infections are limited but they seem to support the use of this drug for the treatment of urinary tract infections [29, 31] . The Table 2 . Fist-line and second-line therapy for the treatment of extended-spectrum-b-lactamase infections. Therapy 'adjustment is recommended depending' on renal 'function' role of fosfomycin vs. meropenem in the definitive treatment of bacteremic urinary tract infections because of ESBL E. coli is assessed in an ongoing large randomized controlled trial (FOREST trial) [32] .
In conclusion, in our opinion the use of carbapenems may be reserved for patients with severe infections caused by ESBL-producing bacteria, and de-escalation therapy should always be performed if feasible ( Table 2 ). The best alternative to carbapenems for the treatment of ESBL infections is represented by BLBLIs, which can be used in patients with BSI caused by ESBL, especially with lower piperacillin/tazobactam MIC (e.g., 16/4 mg/ml) [33, 34] . The use of b-lactams should be maximized by a PK/PD point of view with the administration of high dosages and prolonged infusion strategies maximizing the time above the MIC (t > MIC). A loading dose followed by maintenance doses with extended or continuous infusion is recommended (Table 2) [33] . Although there is less clinical experience to recommend the use of other antibiotics (tigecycline, aminoglycosides, fosfomycin, fluoroquinolones, or trimethoprim/sulfamethoxazole), alternative therapeutic approaches could be considered for ESBL-producing Enterobacteriaceae based on the susceptibility test results.
Carbapenem-resistant Enterobacteriaceae
Carbapenem resistance has been steadily spreading worldwide during the last decade, presenting remarkable geographic variations in the molecular epidemiology [1] [2] [3] (Table 3) . Production of Klebsiella pneumoniae carbapenemase (KPC) enzymes is the most common mechanism of resistance among carbapenemase-producing Enterobacteriaceae 
Carbapenems
The role of carbapenems in infections caused by KPC-Kp is still debated. Among the different combinations, high-dose carbapenem regimens have been associated with better outcome in previous studies [36, 39, 41] . Tumbarello et al. [36] reported that survival rates for combination regimens that included meropenem were 87% at meropenem MICs less than 4 mg/l, 75% at MICs of 8 mg/ l, and 65% at MICs more than 16 mg/l, which was better than the overall survival rate (58%) reported in the study. Daikos et al. [40] also found that patients with KPC-Kp infections who received carbapenem-containing combination regimens had significantly lower mortality rates compared with patients who received noncarbapenem-containing regimens (12 vs 41%; P ¼ 0.006), especially in cases where the MIC of the infecting isolate was less than 4 mg/l. In keeping with these results, a recent study by Tumbarello et al. [39] supported the use of carbapenems for the treatment of KPC-Kp but with some fundamental conditions, such as low carbapenem MIC for the infecting organism ( 8 mg/l), optimal PK/PD exposure to carbapenem, and combination with another active compound.
Clinical experience with therapeutic drug monitoring (TDM) of b-lactams for KPC-Kp remains scarce but it is most likely to be beneficial [48 & ]. For carbapenems, as for other time-dependent agents, the maintenance of concentrations (C trough ) above the MIC for about 40-50% of the time between dosing interval represents the target for bactericidal activity. In KPC-Kp-related infections, however, there is the need to maintain a C trough level above the MIC for the entire dosing interval [49] . Pharmacokinetic data have found that high-dosed, prolonged (continuous or extended) infusion of meropenem could achieve adequate exposures (40% C trough time > MIC) in 100, 75, and 40% of septic patients infected with KPC-Kp isolates with MICs of 4, 8, and 16 mg/l, respectively [37, [50] [51] [52] .
Antibiotics that permeabilize the bacterial cell membrane (e.g., polymyxins), interfere with cell wall synthesis (e.g., fosfomycin), or inhibit protein synthesis (e.g., aminoglycosides or tigecycline) may decrease the MIC sufficiently so that it is exceeded when a carbapenem is coadministered. Therefore, combination therapy should be strongly considered [43, 53] .
In addition, the double-carbapenem regimen (ertapenem and high-dose meropenem or doripenem) has shown to enhance efficacy over either agent alone in previous in-vitro and in-vivo studies and has been recently considered a possible therapeutic strategy in KPC-Kp with high carbapenem MIC or colistin resistance [54 & ,55,56] . The proposed rationale is that ertapenem has a higher affinity to the KPC enzyme, therefore acting as a suicide substrate and allowing the second carbapenem to be protected from the KPC carbapenemase [54 & ,55,56] . Controlled clinical data, however, are needed to determine the efficacy of this treatment. In our opinion, in KPC-Kp with MIC 8-16 mg/l or less meropenem should be administered at high doses and prolonged infusion in combination regimens (with two antibiotics with in-vitro activity) according to TDM. When the MIC is higher than 16 mg/l, carbapenem excluding combination therapy should be performed considering in-vitro activity of antimicrobials (Table 5) . Double-carbapenem regimen is a possible therapeutic strategy in KPC-Kp with colistin resistance (Table 5 ).
Tigecycline
Clinical use of tigecycline for MDR infections has been heterogeneous. Despite different conclusions provided by a notable number of meta-analyses, tigecycline continues to represent a good choice in approved indications and in off-label combination regimens in clinical practice for MDR bacteria [57, 58] .
According to the results of the SENTRY Antimicrobial Surveillance Program, the majority of CRE isolated from European medical centers (88.6%) are susceptible to tigecycline [59] . In the setting of infections caused by MDR pathogens, especially deep-seated infections, a major concern is represented by the correct dose of tigecycline and emergence of reduced susceptibility to this drug, especially if tigecycline is administered as monotherapy [58] [59] [60] [61] .
Sbrana et al. [62] evaluated the effectiveness of carbapenem-sparing combination regimens for treating 26 KPC-Kp infections with high-dose tigecycline and gentamicin or colistin and found that tigecycline was effective for treating 24 of 26 (92%) KPC-Kp infectious episodes.
In our opinion, tigecycline is effective and well tolerated in the treatment of carbapenemaseproducing Enterobacteriaceae, as part of a combination regimen when tigecycline MIC is 1 mg/ml or less. In this setting, we support the use of a high dose (200 mg as a loading dose followed by 100 mg every 12 h) to achieve an adequate PK-PD (Table 5 ) [58] . Although there are few published data, when tigecycline MIC is more than 1, we recommend replacing tigecycline with rifampin (10 mg/kg/ day), as it has been reported to have synergistic activity with colistin against MDR organisms such as KPC-Kp [63] .
Aminoglycosides A significant proportion of KPC-Kp show in-vitro susceptibility to aminoglycosides (usually only to gentamicin) and treatment with an aminoglycoside may be most appropriate as a component of combination therapy for CRE [42, 45] . Concerns are raised about the use of aminoglycosides with colistin because of the high risk of nephrotoxicity [64] .
In our opinion, gentamicin plays an important role in the treatment of KPC-Kp in combination therapy usually with carbapenem or tigecycline. The use of aminoglycosides in association with colistin should be avoided because of the high risk of renal toxicity.
Fosfomycin
Activity of fosfomycin has been tested in many in-vitro studies and has been documented against approximately 73.5-95% of especially KPC-Kp and regimens containing fosfomycin with meropenem have shown to be effective against KPC-Kp [29, 65, 66] . However, clinical experience is very limited. In a recent Greek study involving critically ill patients with various nosocomial infections caused by KPC-producing K. pneumoniae and other MDR Gram-negative bacteria, intravenous fosfomycin was administered in combination with colistin or tigecycline and favorable clinical and microbiological outcomes occurred in a majority (55%) of patients [67] .
There is great concern about the use of fosfomycin as a monotherapy, although the emergence of resistance has been described even when fosfomycin was used in combination therapy [67] . The drug should be usually administered at the dose of 4 g every 6 h but recent data demonstrated that higher doses, up to 24 g/day, are needed to prevent the emergence of bacterial resistance [31] and may be needed in critically ill patients [68] . It must be stressed that the intravenous administration of fosfomycin includes risk of hypokalemia and a high sodium concentration, therefore caution is recommended in patients with liver cirrhosis or heart failure [69] .
In our opinion, we strongly suggest the use of intravenous fosfomycin as part of a combination regimen for the treatment of MDR Enterobacteriaceae, especially in complicated urinary tract infections and sepsis. High-dosed therapy (4 g every 4 h) should be considered to prevent resistance monitoring possible adverse effects [31] .
Colistin
Colistin is considered a highly active in-vitro agent against KPC-Kp [65] . However, its utility is still limited by an overall lack of understanding on how to optimally administer the agent [70] and by nephrotoxicity, which remains a concerning adverse effect of colistin, especially when used at high doses [71] . Nevertheless, a careful management of concomitant factors (e.g., hypoalbuminemia and the use of nephrotoxic drugs) and optimal hydration support can reduce toxicity, especially in critically ill patients [64] . Emergence of resistance to colistin represents a major public health concern in various areas [72] [73] [74] . The high rate of resistance among isolates may be because of the increased use of this drug in recent years, especially as monotherapy and with reduced dose exposures, and may be also related to a genetic background according to the strain type [75, 76] . As resistance to colistin is reported as an independent risk factor for mortality [39, 47, 75] , combination regimens with colistin at high dose are advisable for CRE-susceptible strains. The previously used dose of 3 million international units (MIU) every 8 h has been linked to insufficient concentrations in critically ill patients and the current recommended dosage is 9 MIU loading dose followed by 4.5 MIU every 12 h [77] .
Randomized clinical trials aiming to compare colistin alone and colistin and meropenem for CRE infections are ongoing in the United States and in Europe (NCT01597973 and NCT01732250). Findings from these studies are expected to provide valuable information on the efficacy of these approaches when optimized doses are used [43] .
The optimal regimen for the treatment of colistin-resistant strains is unknown [58, 78] . In two previous Italian studies [44, 79] , the combination of colistin and rifampicin showed synergistic antimicrobial activity and postantibiotic effect against KPC-producing K. pneumoniae colistin-resistant strains isolated from different pathological samples. These results were probably related to the ability of colistin to disrupt the bacterial membrane integrity that allows the access and accumulation of rifampicin [63] . The clinical efficacy of polymyxin B and doripenem has also been reported against clinical isolates of colistin-resistant KPC-Kp [80] .
In our opinion, in the setting of the treatment of CRE, we suggest to include colistin in combination regimens at high doses (9 million units, as a loading dose followed by 4.5 million units mg every 12 h in a patient with normal renal function) with careful management of toxicities [64] . If resistance to colistin is documented, the addition of rifampicin may be considered to exploit synergism.
New antibiotics
Novel antimicrobials that could provide clinical efficacy toward MDR Gram-negative pathogens are urgently needed. Food and Drug Administration recently approved two novel combination antibiotics, ceftolozane-tazobactam and ceftazidime-avibactam. Both of these combination agents have shown in-vitro activity against selected resistant Gram-negative pathogens, including Enterobacteriaceae and P. aeruginosa [81] . Spectrum of activity of ceftolozane/tazobactam includes difficultto-treat Gram-negative pathogens, including ESBL strains [21, [82] [83] [84] . Notably, ceftazidime/avibactam has demonstrated consistent activity against KPC-Kp [21, 85] (Table 6 ).
Other inhibitor combinations that have at least completed phase 1 clinical trials are ceftaroline fosamil/avibactam, imipenem/relebactam, meropenem/RPX7009. An overview of emerging treatment options for MDR Enterobacteriaceae is reported in Table 6 .
Infection control measures
Infection control interventions to contain CRE outbreaks are usually implemented in the form of bundles as no one action can be singled out as effective.
The key components of a successful bundle are yet to be determined, although most include increased hand hygiene, contact precautions, and stewardship programs [86] [87] [88] [89] (Table 7) . Other infection prevention strategies such as decolonization of patients by the use of daily chlorhexidine bathing and decontamination of the environment have demonstrated a reduction in the acquisition of MDR Gram-negative bacteria [88] . In addition, a recent meta-analysis on ESBL and CRE has shown selective oral, digestive, or intravenous decontamination strategies to be well tolerated and possibly effective during therapy but success at decolonization may favor the emergence of resistant strains and long-term effects are unclear [90 && ].
CONCLUSION
Current clinical practice relating to Enterobacteriaceae infections has been extremely challenged by the emergence of MDR. There is great concern about the therapeutic future options as only very few agents may address the unmet medical needs. Currently, the most effective approach is the optimized use of the currently available antibiotics. Combination therapy seems to be important to ensure adequate coverage of the patient and improve clinical outcome. However, randomized clinical trials are urgently needed to define the possible benefit from combinations in various settings. Most importantly, infection control measures and prompt diagnostics are the cornerstones to prevent further transmission of MDR pathogens in healthcare settings and to optimize early antimicrobial treatment. 
